Role of Famotidine in the Clinical Improvement of COVID-19 Patients.

Role of Famotidine in the Clinical Recovery and Symptomatic Improvement of COVID-19 Patients.

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04504240

Enrollment

208

Registered

2020-08-07

Start date

2020-08-01

Completion date

2021-04-15

Last updated

2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Keywords

COVID 19, Famotidine, Bangladesh

Brief summary

This study is aimed to investigate the effect of Famotidine in the clinical recovery of COVID-19 patients. COVID19 is a worldwide pandemic. Hence SARS-CoV-2 is a novel virus; there is no specific medication against it. Like other countries of the world, Besides antiviral drugs, immunosuppressive agents, and symptomatic therapy like H2 receptor blocker FAMOTIDINE came to the limelight due to its role in reducing the symptoms of COVID-19 patients. The study will include COVID-19 participants to confirm by RT PCR or an HRCT chest. Detail history of each participant with comorbidity will be taken and will be examined carefully. The hospitalized patients admitted to the HDU/ICU units will be enrolled in this study. Critically ill patients who require ventilator support will not be included in this study. The outcome of the Famotidine treatment will be evaluated and compared with a control group.

Interventions

DRUGFamotidine 20 MG

Famotidine; tablet Famotac 20mg oral form.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

16 Years to 80 Years

Healthy volunteers

Inclusion criteria

* SARS-CoV-2 infection confirmed by RT PCR or CT Chest. * Severe COVID-19 patients require hospitalization under HDU/ICU.

Exclusion criteria

* Patients with severe and/or uncontrolled medical conditions with significantly compromised organ function. * Patients who were hospitalized from the before due to other reasons. * Contraindication / possible drug interaction with Famotidine with existing therapy. * Immunocompromised patients. * Pregnancy, Pulmonary Tuberculosis, AIDS

Design outcomes

Primary

Measure	Time frame	Description
Time to Clinical Improvement (TTCI)	Following randomization 30days.	Time to clinical improvement (TTCI) was defined as time from randomization to National Early Warning Score 2 (NEWS2) Score of ≤2 maintained for 24 Hours.
Time to symptomatic recovery.	Following randomization 30 days.	Time to Symptomatic recovery was defined as the duration (in days) that required for the relief of the COVID-19 symptoms from the day of hospitalization.

Secondary

Measure	Time frame	Description
Duration of ICU Stay.	Following randomization 30 days.	Duration of ICU Stay in days.
Time to clinical failure or death.	Following randomization 30 days.	Time to clinical failure, defined as the time from randomization to the first occurrence of death, mechanical ventilation or withdrawal (whichever occurs first).
Time to Viral clearance / COVID-19 recovery.	Following randomization 60 days.	This was defined as the duration (in days) from the first positive PCR to the first negative PCR (Confirmed by a repeat negative PCR after 7days) for SARS-Cov-2 infection following hospital discharge.
Total hospital stay.	Following randomization 30 days.	Time from randomization to hospital discharge or Ready for discharge (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient Air or ≤4L supplemental oxygen).
Mortality Rate	Following randomization 30 days.	Mortality Rate in percentage in study groups.

Countries

Bangladesh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026